Astec LifeSciences Limited announced its audited financial results for the quarter and financial year ended March 31, 2026, during its Board Meeting held on April 27, 2026. For the quarter ended March 31, 2026, the company reported consolidated total income of ₹127.31 Crore, reflecting a marginal growth of 1.41% compared to ₹125.54 Crore in the previous quarter (Q3 FY26) and a 5.83% increase from ₹120.30 Crore in the corresponding quarter of the previous year (Q4 FY25). Despite the revenue growth, the company faced continued pressure on profitability, reporting a net loss of ₹45.89 Crore for the current quarter. This represents a significant widening of losses compared to the ₹15.70 Crore loss in Q3 FY26 and the ₹134.70 Crore net loss reported for the full fiscal year 2025. The Board also approved the appointment of Mr. Vishal Sharma as an Additional Director and Chairperson, succeeding Mr. Nadir Godrej who retired effective April 13, 2026.

*Calculated based on available quarterly trends and annual net loss of ₹134.7 Cr for FY25.

Astec LifeSciences Limited, a subsidiary of Godrej Agrovet Limited, is a prominent Indian company engaged in the manufacturing of agrochemical active ingredients and pharmaceutical intermediates. The company operates in both the enterprise and Contract Development and Manufacturing Organization (CDMO) segments, with a geographically diversified revenue profile where exports contribute approximately 60% of total sales. Recent 2025 updates include a successful rights issue of ₹237 Crore in July 2025 to strengthen its capital structure amidst a challenging global demand environment and inventory overstocking issues. Notable institutional investors include Godrej Industries Limited, which held a 67.03% stake as of December 31, 2025, alongside Nippon Life India Asset Management and ICICI Prudential Asset Management. The company continues to focus on enhancing capacity utilization and pruning capital expenditure to navigate market volatilities and improve long-term profitability.